1. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer
- Author
-
Gill, Jennifer, Cetnar, Jeremy Paul, and Prasad, Vinay
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Lung Cancer ,Rare Diseases ,Cancer ,Lung ,Prevention ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Good Health and Well Being ,Clinical Trials as Topic ,Drug Approval ,Humans ,Immune Checkpoint Inhibitors ,Lung Neoplasms ,Progression-Free Survival ,Research Design ,Small Cell Lung Carcinoma ,Time Factors ,United States ,United States Food and Drug Administration ,FDA ,immunotherapy ,small cell lung cancer ,surrogate endpoints ,Oncology and carcinogenesis - Abstract
In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.
- Published
- 2020